TenNor Therapeutics' rifasutenizol triple therapy achieved a >90% eradication rate in treating _Helicobacter pylori_ (_H. pylori_) infection, surpassing the current standard bismuth-containing quadruple therapy (BQT).
TenNor Therapeutics' rifasutenizol triple therapy achieved a >90% eradication rate in treating Helicobacter pylori (H. pylori) infection in a Phase III trial.
TenNor Therapeutics' rifasutenizol-based triple therapy achieved a >90% eradication rate in H. pylori-infected patients, surpassing the standard bismuth-containing quadruple therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.